PipelineReview.com8h
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson’s Disease
Vesalius Will Apply its Proprietary Platform to Identify Novel Intervention Points that GSK may Advance for the Treatment of Patients with Parkinson’s Disease GSK has Licensed a Preclinical Small ...
PipelineReview.com8h
Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology
Collaboration will leverage Flare Therapeutics’ proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecules ...
PipelineReview.com10h
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
SAN DIEGO, CA, USA I November 11, 2024 I Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines ...
PipelineReview.com10h
Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial
DARMSTADT, Germany I 12, 2024 I Merck, a leading science and technology company, today announced that the Phase III MANEUVER trial of pimicotinib, an ...
PipelineReview.com1d
STORM Therapeutics Presents New Clinical Data on its First-in-Class METTL3 Inhibitor STC-15 at SITC 2024
CAMBRIDGE, UK I November 11, 2024 I STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it ...
PipelineReview.com1d
Next Generation Gene Therapeutics (NGGT) Announces Positive New Data on NGGT002 for the Treatment of Phenylketonuria (PKU)
NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the treatment of Phenylketonuria ...
PipelineReview.com1d
Theragent and CellVax Therapeutics Announce First Patient Dosed in Phase 2 Trial of FK-PC101, a Novel Personalized Cancer Immunotherapy
ARCADIA, CA, USA I 11, 2024 I Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced a ...
PipelineReview.com3d
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M17D1 in Advanced Solid Tumors
REDMOND, WA, USA I November 8, 2024 I SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational ...
PipelineReview.com3d
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
LOS ANGELES, CA, USA I November 8, 2024 I Nammi Therapeutics, Inc. (Nammi), a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC) and Nammisome ...
PipelineReview.com3d
Mabwell Reveals Encouraging Pre-clinical Data of 7MW4811 at the 15th World ADC Conference
SHANGHAI, China I November 8, 2024 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the “Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based ...
PipelineReview.com3d
Aummune Announces Results from Phase 1 Trial of its Novel AM003 Immunotherapy for the Treatment of Solid Tumors
“Immunotherapy and personalized therapy has transformed cancer treatment. However, there is still a dire need for new innovative therapies. We believe that AM003 — as a new class of individualized ...
PipelineReview.com3d
OncoResponse Announces Phase 1 Results of the Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer
Late-Breaker Poster Presentation to occur at the 39th Annual Society for Immunotherapy of Cancer (SITC) conference on November 9th, 2024 - ...